Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015', provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 11 Therapeutics Development 12 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 12 Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 13 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 14 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Investigation by Universities/Institutes 17 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 22 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Investigation by Universities/Institutes 25 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 26 AnGes MG, Inc. 26 AstraZeneca PLC 27 Bayer AG 28 Biosidus S.A. 29 Biscayne Pharmaceuticals, Inc. 30 Bristol-Myers Squibb Company 31 Cardiome Pharma Corp 32 CardioVascular BioTherapeutics, Inc. 33 Eagle Pharmaceuticals, Inc. 34 Gilead Sciences, Inc. 35 Hemostemix Ltd 36 Human Stem Cells Institute 37 Isis Pharmaceuticals, Inc. 38 Juventas Therapeutics, Inc. 39 Lacer, S.A. 40 Lee's Pharmaceutical Holdings Limited 41 Lonestar Heart, Inc. 42 MedImmune, LLC 43 Merck & Co., Inc. 44 Miltenyi Biotec GmbH 45 Multi Gene Vascular Systems Ltd 46 Nuo Therapeutics, Inc. 47 Pluristem Therapeutics Inc. 48 Regado Biosciences, Inc. 49 The Medicines Company 50 ViroMed Co., Ltd. 51 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 ACP-01 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ALD-201 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 anacetrapib - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Aptamers for Cardiovascular Diseases - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 BAY-606583 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 beperminogene perplasmid - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Biglycan Therapy for Cardiovascular Diseases - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 BIS-5409 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 bivalirudin - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 bivalirudin - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 BQ-123 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 C2 ceramide - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 C6 ceramide - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 cangrelor - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 CAP-1002 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Cryocell - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 CVBT-141H - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Gemacell - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Gene Therapy to Activate VEGF for Ischemia - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 ISIS-APOARx - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 ISIS-CRPRx - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 JVS-100 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 LA-419 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 MEDI-6012 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 MultiGeneGraft - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 MZ-004 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Proteins for Ischemic Heart Disease - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 ranolazine ER - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 rivaroxaban - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 Small Molecule for Coronary Artery Disease - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 Synthetic Peptides to Modulate CD36 Receptor for Ischemic Heart Disease and Macular Degeneration - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 tirofiban hydrochloride - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 VM-202 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 XL-652 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 ZK-001 - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 127 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 155 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 158 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 159 Featured News & Press Releases 159 Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago 159 Oct 27, 2014: The Medicines Company Wins Favorable Judgment in Angiomax (Bivalirudin) Patent Litigation 159 Oct 06, 2014: Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs) 160 Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APO(A)RX At European Society of Cardiology Congress 2014 160 Jul 07, 2014: The Medicines Company Receives Market Authorization Renewal for Angiox (Bivalirudin) from the European Medicines Agency and the European Commission 161 Apr 28, 2014: The Medicines Company Files Petition Against Aurobindo Over Patent Infringement 162 Mar 30, 2014: Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax Presented at ACC.14 162 Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor 163 Oct 11, 2013: Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT 164 Oct 09, 2013: First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax in Patients Undergoing Peripheral Endovascular Procedures 164 Appendix 166 Methodology 166 Coverage 166 Secondary Research 166 Primary Research 166 Expert Panel Validation 166 Contact Us 167 Disclaimer 167
List of Tables Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 12 Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Comparative Analysis by Unknown Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Development by Companies, H1 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2015 25 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2015 26 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2015 27 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2015 28 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H1 2015 29 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 30 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2015 31 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2015 32 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 33 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 34 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2015 35 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H1 2015 36 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2015 37 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 38 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H1 2015 39 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H1 2015 40 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 41 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2015 42 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2015 43 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2015 44 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2015 45 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 46 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H1 2015 47 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2015 48 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Regado Biosciences, Inc., H1 2015 49 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2015 50 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2015 51 Assessment by Monotherapy Products, H1 2015 52 Number of Products by Stage and Target, H1 2015 54 Number of Products by Stage and Mechanism of Action, H1 2015 56 Number of Products by Stage and Route of Administration, H1 2015 58 Number of Products by Stage and Molecule Type, H1 2015 60 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2015 127 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2015 155 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H1 2015 156 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H1 2015 157 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2015 158
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.